Research Open Terminal →
BIIB

Biogen Inc. Common Stock

XNAS · BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) · BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

1 article20 insider tx0 holders0 supply chain0 selling intent filings0 new insiders

Research articles

Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.

View all articles →

Recent insider activity

Date Insider Title Type Shares Price Value
5/1/2026 Keeney Adam Head of Corporate Development OPTION_EXERCISE -939
5/1/2026 Keeney Adam Head of Corporate Development TAX_WITHHOLD -455 $187 $85,112
5/1/2026 Keeney Adam Head of Corporate Development OPTION_EXERCISE 939
4/1/2026 Godbout Sean Chief Accounting Officer OPTION_EXERCISE 181
4/1/2026 Godbout Sean Chief Accounting Officer TAX_WITHHOLD -54 $184 $9,924
4/1/2026 Godbout Sean Chief Accounting Officer OPTION_EXERCISE -181
2/13/2026 Viehbacher Christopher President and CEO GRANT 38,015
2/13/2026 Singhal Priya Head of Development GRANT 10,560
2/13/2026 Murphy Nicole Head of Pharm Ops and Tech GRANT 10,560
2/13/2026 Kramer Robin Chief Financial Officer GRANT 8,450
2/13/2026 Keeney Adam Head of Corporate Development GRANT 8,025
2/13/2026 Izzar Rachid Head of Global Product Strat. GRANT 7,390
2/13/2026 Grogan Jane Head of Research GRANT 8,450
2/13/2026 Gregory Ginger EVP, Human Resources GRANT 8,025
2/13/2026 Godbout Sean Chief Accounting Officer GRANT 1,800
2/13/2026 ALEXANDER SUSAN H EVP Chief Legal Officer GRANT 8,450
2/12/2026 Murphy Nicole Head of Pharm Ops and Tech BUY 3 $195 $585
2/9/2026 Singhal Priya Head of Development SELL -2,660 $200 $531,548
2/6/2026 Viehbacher Christopher President and CEO OPTION_EXERCISE 9,008
2/6/2026 Viehbacher Christopher President and CEO TAX_WITHHOLD -4,356 $201 $876,340
Want deeper analysis?
Investabot monitors SEC filings daily and generates institutional-grade research on insider trades, risk factors, supply chains, and more.
Open the Terminal — Free →